References
- Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science 2012;336:647.
- Pappas PG, NIAID Mycoses Study Group, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634–43.
- Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids 2009; 23:525–30.
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016;62:e1–50.
- Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760–3.
- Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56:1724–32.
- de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, et al. Candida infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. Front Microbiol 2018;9:1351.
- Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006;19:130–9.
- Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol 2016;7:2173.
- Kale P, Johnson LB. Second-generation azole antifungal agents. Drugs Today (Barc) 2005;41:91–105.
- Pouliot M, Jeanmart S. Pan assay interference compounds (PAINS) and other promiscuous compounds in antifungal research. J Med Chem 2016; 59:497–503.
- Na YM, Le BM, Pagniez F, et al. Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives. Eur J Med Chem 2003;38:75–87.
- Pagniez F, Le Borgne M, Marchand P, et al. In vitro activity of a new antifungal azolyl-substituted indole against Aspergillus fumigatus. J Enzyme Inhib Med Chem 2002;17:425–9.
- Marchand P, Le Borgne M, Na YM, et al. Synthesis and antileishmanial activity of 3-(alpha-azolylbenzyl)indoles. J. Enzyme Inhib Med Chem 2002;17:353–8.
- Na YM, Lebouvier N, Le Borgne M, et al. Synthesis and antileishmanial activity of 3-imidazolylalkylindoles. Part I. J Enzyme Inhib Med Chem 2004;19:451–7.
- Price MF, Cawson RA. Phospholipase activity in Candida albicans. Sabouraudia 1977;15:179–85.
- Mago N, Khuller GK. Subcellular localization of enzymes of phospholipid metabolism in Candida albicans. J Med Vet Mycol 1990;28:355–62.
- Rossoni RD, Barbosa JO, Vilela SF, et al. Correlation of phospholipase and proteinase production of Candida with in vivo pathogenicity in Galleria mellonella. Braz J Oral Sci 2013;12:199–204.
- Fule SR, Das D, Fule RP. Detection of phospholipase activity of Candida albicans and non albicans isolated from women of reproductive age with vulvovaginal candidiasis in rural area. Indian J Med Microbiol 2015;33:92–5.
- Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000;13:122–43.
- Pugh D, Cawson RA. The cytochemical localization of phospholipase A and lysophospholipase in Candida albicans. Sabouraudia 1975;13:110–5.
- Köhler GA, Brenot A, Haas-Stapleton E, et al. Phospholipase A2 and phospholipase B activities in fungi. Biochim Biophys Acta 2006;1761:1391–9.
- Schevitz RW, Bach NJ, Carlson DG, et al. Structure-based design of the first potent and elective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol 1995;2:458–65.
- Binder U, Lass-Flörl C. Epidemiology of invasive fungal infections in the Mediterranean. Mediterr J Hematol Infect Dis 2011;3:e20110016.
- (a) Le Borgne M, Na YM, Pagniez F, et al. Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition. US 0067998. 2004; (b) Lebouvier N, Giraud F, Corbin T, et al. Efficient microwave-assisted synthesis of 1-(1H-indol-1-yl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. Tetrahedron Lett 2006;47:6479–83; (c) Lebouvier N, Pagniez F, Duflos M, et al. Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. Bioorg Med Chem Lett 2007;17:3686–9.
- Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards Reference method for broth dilution susceptibility testing of yeasts: approved standard, 2nd ed. Document M27-A2. Clinical and Laboratory Standards Institute. 2002; Wayne P.
- Alvarez-Rueda N, Fleury A, Morio F, et al. Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance. PLoS One 2011;6:e21239.
- Scorzoni L, de Paula E, Silva AC, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol 2017;8:36.
- Roberts CW, McLeod R, Rice DW, et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003;126:129–42.
- Le Pape P, Zidane M, Abdala H, More MT. A glycoprotein isolated from sponge, Pachymatisma johnstonii, has anti-leishmanial activity. Cell Biol Intern 2000;24:51–6.
- Senda K, Yoshioka H, Doke N, Kawakita K. A cytosolic phospholipase A2 from potato tissues appears to be patatin. Plant Cell Physiol 1996;37:347–53.